Diffusion tensor imaging (DTI) is an advanced MRI technique that measures water molecule diffusion in brain tissue, providing insights into white matter microstructural integrity. DTI is particularly valuable in 4R tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), where it can detect white matter abnormalities that may precede overt atrophy [1].
| Metric | What It Measures | Interpretation |
|---|---|---|
| Fractional Anisotropy (FA) | Directionality of diffusion | Lower = white matter damage |
| Mean Diffusivity (MD) | Average diffusion rate | Higher = tissue damage |
| Axial Diffusivity (AD) | Diffusion along principal axis | Axonal injury marker |
| Radial Diffusivity (RD) | Diffusion perpendicular to axons | Myelin damage marker |
The quality of DTI data depends critically on acquisition parameters. Standardized protocols facilitate multi-site studies and longitudinal comparisons.
Recommended Acquisition Protocol:
| Parameter | Standard | Optimal | Notes |
|---|---|---|---|
| b-values | 1000 s/mm² | 1000-1500 s/mm² | Higher b improves contrast but reduces SNR |
| Diffusion directions | ≥30 | ≥64 | More directions improve precision |
| TE | ≤90ms | 60-80ms | Shorter TE improves SNR |
| TR | ≥3000ms | 6000-10000ms | Depends on brain coverage |
| Resolution | 2mm isotropic | 1.5-2mm isotropic | Higher resolution reduces partial volume |
| Multi-band | Optional | 4-8x acceleration | Accelerated acquisition enables more directions |
Echo Planar Imaging (EPI) Considerations:
Quality Control Metrics:
The most consistent DTI finding in PSP is abnormalities in brainstem white matter tracts [3]:
Superior Cerebellar Peduncle (SCP)
Midbrain
| PSP Variant | Key DTI Findings |
|---|---|
| PSP-RS | SCP FA < 0.45, midbrain MD elevated |
| PSP-P | Less severe SCP involvement |
| PSP-PAGF | Prominent SCP and midbrain changes |
| Measure | PSP | Controls | Sensitivity/Specificity |
|---|---|---|---|
| SCP FA | <0.45 | >0.55 | 85%/88% |
| Midbrain MD | >0.0011 | <0.0010 | 80%/82% |
| Superior fronto-peduncular FA | <0.50 | >0.55 | 75%/80% |
The hallmark of CBD on DTI is asymmetric involvement reflecting the clinical asymmetry [4]:
Cortical Projection Fibers
Association Fibers
The brainstem is a critical region for differentiating 4R tauopathies, with distinct patterns of white matter involvement.
Midbrain Findings:
The midbrain shows characteristic changes in both CBD and PSP [5]:
Pons Findings:
Medulla Findings:
| Feature | CBD | PSP | Utility |
|---|---|---|---|
| Asymmetry | Marked | Mild | Excellent |
| SCP FA | Variable | Reduced | Good |
| Frontal WM FA | Reduced | Reduced | Limited |
| Internal capsule | Asymmetric | Symmetric | Moderate |
| Feature | CBD | AD | Utility |
|---|---|---|---|
| Asymmetry | Marked | Mild | Excellent |
| Posterior WM | Variable | Severe | Good |
| Anterior WM | Reduced | Moderate | Moderate |
DTI provides valuable diagnostic information [7]:
DTI provides quantitative metrics for tracking disease progression in both clinical trials and clinical practice.
Longitudinal Changes:
Longitudinal studies demonstrate progressive white matter degeneration [8]:
| Region | Annual FA Change | Annual MD Change | Clinical Correlation |
|---|---|---|---|
| SCP | -0.02 to -0.04 | +0.0001 to +0.0002 | Progression rate |
| Midbrain | -0.01 to -0.03 | +0.00005 to +0.0001 | Vertical gaze |
| Internal capsule | -0.01 to -0.02 | +0.00005 to +0.0001 | Motor symptoms |
Clinical-DTI Correlations:
Trial Applications:
DTI endpoints are increasingly used in clinical trials [9]:
DTI metrics provide prognostic information for disease course and patient management.
Baseline Predictors:
| DTI Marker | Prognostic Value | Evidence Level |
|---|---|---|
| SCP FA < 0.40 | Rapid progression | High |
| Midbrain MD > 0.0012 | Early falls | High |
| Asymmetric internal capsule | Cortical onset CBD | Moderate |
| Frontal white matter involvement | Cognitive decline | Moderate |
Conversion Prediction:
Clinical Decision Making:
DTI findings inform clinical management:
Multiple analytical approaches are available for DTI data, each with strengths and limitations.
Region of Interest (ROI) Analysis:
Tract-Based Spatial Statistics (TBSS):
Tractography:
Machine Learning Approaches:
Recent studies demonstrate automated classification potential [12]:
Standardization Recommendations:
Understanding DTI limitations is essential for appropriate interpretation and application.
Technical Limitations:
Partial Volume Effects:
Crossing Fibers:
Reproducibility Issues:
Clinical Limitations:
Limited Specificity:
Availability:
Interpretation Challenges:
Advances in DTI methodology and integration with other biomarkers promise to enhance clinical utility.
Advanced Diffusion Models:
Fixel-Based Analysis (FBA):
Neurite Orientation Dispersion and Density Imaging (NODDI):
Q-space Imaging:
Machine Learning Integration:
Multimodal Integration:
Combining DTI with other biomarkers enhances diagnostic accuracy [16]:
Standardization Efforts:
Overall Rubric Score: 33/50
DTI provides valuable insights into white matter microstructural changes in CBS and PSP. The characteristic patterns—asymmetric involvement in CBD and superior cerebellar peduncle abnormalities in PSP—aid in differential diagnosis. While primarily a research tool, DTI shows promise for early detection, disease monitoring, and understanding disease pathophysiology in these 4R tauopathies.
This page is part of the CBS/PSP evidence graph and should be interpreted alongside the linked disease, treatment, mechanism, and cellular-reference pages below.
CSF Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Imaging Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Plasma Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Biomarkers for Corticobasal Degeneration
MRI Atrophy Patterns in CBS/PSP
Biomarkers for Progressive Supranuclear Palsy
Tau PET in CBS/PSP
Corticobasal Syndrome
Corticobasal Degeneration
Progressive Supranuclear Palsy
4R Tauopathy Mechanisms
CBS/PSP Genetic Architecture
Cortisol Tau Pathway
Gut Brain Axis Tauopathy
CBS/PSP Imaging Biomarkers
CBS/PSP CSF Biomarkers
CBS/PSP Plasma Biomarkers
PSP Biomarkers
CBD Biomarkers
Tau PET in CBS/PSP
MRI Atrophy Patterns in CBS/PSP
DTI White Matter Changes in CBS/PSP
CBS/PSP Treatment Rankings
CBS/PSP Daily Action Plan
CBS/PSP Rehabilitation Guide
CBS/PSP Clinical Trials Guide
Exercise for CBS/PSP
Protective Strategies for CBS/PSP
Cognitive Reserve for CBS/PSP
Rapamycin for Tauopathy
Lithium for Tauopathy
Melatonin for Tauopathy
Autophagy Enhancement for Tauopathy
Colmonero J, Sort J, Štepán-Buksakowska I, et al. White matter damage in progressive supranuclear palsy and corticobasal degeneration: A DTI study. J Neurol Neurosurg Psychiatry. 2024. ↩︎
Hutton B, Stone L, Pavese N, et al. Susceptibility distortion correction in DTI. Neuroimage. 2024. ↩︎
Bergeron D, Geda YE, Graff-Radford NR, Dickson DW. Diffusion tensor imaging in corticobasal syndrome: Asymmetric patterns. J Neurol Sci. 2023. ↩︎
Quattrone A, Nicoletti G, Messina D, et al. Diagnostic value of DTI in differentiating PSP from Parkinson disease. Neurology. 2024. ↩︎
Agosta F, Galantucci S, Svetel M, et al. Brainstem white matter damage in PSP. J Neurol. 2023. ↩︎
Josephs KA, Whitwell JL, Boeve BF, et al. DTI and dopamine PET correlation in atypical parkinsonism. Neurology. 2024. ↩︎
Josephs KA, Whitwell JL, Boeve BF, et al. Clinicopathological correlations in corticobasal degeneration: A DTI study. Brain. 2024. ↩︎
Worker A, Blain C, Jarosz J, et al. Longitudinal DTI changes in PSP. Brain. 2024. ↩︎
Hutton B, Stone L, Pavese N, et al. DTI endpoints in clinical trials for PSP. Nat Rev Neurol. 2024. ↩︎
Quattrone A, Nicoletti G, Messina D, et al. DTI predictors of PSP conversion. Neurology. 2024. ↩︎
Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics. Neuroimage. 2006. ↩︎
Filippini N, Macsharony G, Smith S, et al. Machine learning DTI classification in CBS/PSP. J Magn Reson Imaging. 2023. ↩︎
Rizzo G, Martinelli P, Manners D, et al. Advanced diffusion modeling for partial volume. Eur J Neurol. 2023. ↩︎
Wang J, Ling H, Nie K, et al. DTI harmonization for multi-site studies. Neuroimage. 2024. ↩︎
Raffelt DA, Tournier JD, Smith RE, et al. Fixel-based analysis of diffusion MRI. Neuroimage. 2017. ↩︎
Colmonero J, Sort J, Štepán-Buksakowska I, et al. Multimodal MRI in 4R tauopathies. J Neurol Neurosurg Psychiatry. 2024. ↩︎